LOS ANGELES, CA / ACCESSWIRE / August 30, 2024 / Quantum BioPharma Ltd. (QNTM) marks a significant milestone with the successful launch of unbuzzd™ on Amazon. This development coincides with the Company's rebranding and ticker change to QNTM. Additionally, recent ethics approval in Australia for a Phase-1 study of Lucid-MS represents a crucial advancement in the development of a novel treatment for Multiple Sclerosis.
We maintain our Buy-Venture rating and have adjusted our target price to $12.80 per share, reflecting confidence in Quantum BioPharma's pioneering efforts in addressing brain disorders and alcohol health. The Company's strong pipeline includes Lucid-MS, targeting progressive Multiple Sclerosis, and unbuzzd™, a formulation designed to expedite alcohol metabolism. With marketing experts Kevin Harrington and Gerry David leading unbuzzd™'s market launch, Quantum BioPharma is positioned for substantial growth.
For access to our research report on Quantum BioPharma, please click here.
For more information on Quantum BioPharma, visit www.QuantumBioPharma.com.
For more information on Singular Research, visit www.SingularResearch.com.
Singular Research
[email protected]
818-222-6234
SOURCE: Singular Research